LeafNLP Demos
Back to explore

Report #2885892

Received Feb 17, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
CA
Recovered
Unknown
Vaccinated
Nov 18, 2025
Onset
Jan 30, 2026
Days to onset
73
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (HEPLISAV-B)DYNAVAX TECHNOLOGIES CORPORATION1946907—

Symptoms (1)

Extra dose administered

Symptom narrative

Patient Had A Dose of Heplisav-B on 11/18/2025, and Then A Pediatric Dose of Engerix on 1/30/2025; Initial report received on 02-Feb-2026. A nurse reported that a 31-year-old female patient (race, ethnicity not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and received a a pediatric dose of ENGERIX-B more than two months later. No medical history or concomitant medications were reported. On 18-Nov-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #946907, expiration date 23-Nov-2027, and NDC number route and site not reported). 30-Jan-2026, 73 days after having been vaccinated with HEPLISAV-B, the patient received a pediatric dose of a hepatitis B vaccine [ENGERIX-B (no details provided)]. The patient had no other side effects. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.